Dow Jones
38.503,09 +263,11 (+0,69%) Nasdaq
15.691,94 +240,64 (+1,56%) Nikkei 225
37.552,16 +113,55 (+0,30%) EUR/USD
1,0702 +0,0046 (+0,43%) Bitcoin EUR
62.297,52 +520,14 (+0,84%) CMC Crypto 200
1.435,27 +20,51 (+1,45%)
DBV Technologies S.A. (DBVT)
| Chiusura precedente | 0,6600 |
| Aperto | 0,6900 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,6602 - 0,7148 |
| Intervallo di 52 settimane | 0,6500 - 2,3700 |
| Volume | |
| Media Volume | 53.653 |
| Capitalizzazione | 129,908M |
| Beta (5 anni mensile) | 0,76 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3800 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 4,91 |
GlobeNewswireDBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a
- GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2023 96,253,553 Total gross of voting rights: 96,253,553 Total net* of voting rights: 96,076,898 * Net total = total number of voting rights attached to shares – shares
- GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, September 5, 2023 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the company will participate in the H.C. Wainwright Annual Global Investment Conference taking place on September 11th −13th in New York, NY. Daniel Tassé, Chief Executive Officer, will represent the company in a fireside chat session on Tuesday, September
